Glenmark USA faces US antitrust lawsuits alleging price-fixing and anti-competitive conduct since 2016. • Over 35 complaints from multiple plaintiffs and 46 state attorneys general consolidated. • Glenmark USA denies allegations but agrees to a $29.6M settlement over 5 years. • Settlement won't significantly impact Glenmark's financial position; amount already provided in financials. Background on Litigation: Glenmark Pharmaceuticals' US subsidiary, Glenmark USA, has been named in over 35 complaints since 2016. Allegations include price-fixing, market allocation, and anti-competitive conduct related to generic pharmaceuticals pricing. Plaintiffs include direct and indirect purchasers, private plaintiffs, and 46 state attorneys general. Some state lawsuits shifted venue to Connecticut in 2024. Settlement Details: Glenmark USA agreed to settle with state attorneys general for $29.628 million. Payment to be made in annual instalments over 5 years. Settlement is subject to court approval. Glenmark USA denies all allegations; settlement is not an admission of liability or wrongdoing. Financial Implications: Glenmark has already accounted for the full settlement amount in its financial statements. Company states settlement will not significantly impact its financial position. $GLENMARK